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Abstract
Background: Recent studies suggest that HMG-CoA reductase inhibitors ("statins") may have
beneficial effects for patients at risk for some types of infections. We examined the effect of prior
outpatient use of statins on mortality for patients hospitalized with community-acquired
pneumonia.
Methods: A retrospective cohort study conducted at two tertiary teaching hospitals. Eligible
subjects were admitted with a diagnosis of, had a chest x-ray consistent with, and had a discharge
ICD-9 diagnosis of pneumonia. Subjects were excluded if they were "comfort measures only" or
transferred from another acute care hospital. Subjects were considered to be on a medication if
they were taking it at the time of presentation.
Results: Data was abstracted on 787 subjects at the two hospitals. Mortality was 9.2% at 30-days
and 13.6% at 90-days. At presentation 52% of subjects were low risk, 34% were moderate risk, and
14% were high risk based on the pneumonia severity index. In the multivariable regression analysis,
after adjusting for potential confounders including a propensity score, the use of statins at
presentation (odds ratio 0.36, 95% confidence interval 0.14–0.92) was associated with decreased
30-day mortality.
Discussion:  Prior outpatient statin use was associated with decreased mortality in patients
hospitalized with community-acquired pneumonia despite their use being associated with comorbid
illnesses likely to contribute to increased mortality. Confirmatory studies are needed, as well as
research to determine the mechanism(s) of this protective effect.
Background
Community-acquired pneumonia is the seventh leading
cause of death and the leading cause of infectious death in
the United States [1]. Although mortality due to commu-
nity-acquired pneumonia decreased significantly with the
introduction of antibiotics in the 1950s, since that time
mortality has been stable or increasing [2]. Despite this,
only a few new classes of antibiotics have been added to
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the armamentarium for treating community-acquired
pneumonia in the last 20 years and no new classes of
medications beyond antibiotics have been added since
the 1950s.
Recent studies have demonstrated that inhibitors of
HMG-CoA reductase ("statins") have significant immu-
nomodulatory effects and reduce systemic cytokine levels
[3-8]. These cytokines play an important role in host
defense mechanisms for patients with community-
acquired pneumonia but under certain conditions may
lead to septic shock or acute respiratory distress syndrome
(ARDS) [9-11]. Recent studies have demonstrated that in
patients hospitalized with bacteremia or diabetic lower
extremity infections those patients who were taking stat-
ins had a significantly decreased odds of death after
adjusting for other potential confounders [12,13].
The study aim was to assess the effects of prior outpatient
statin use on 30-day mortality for patients hospitalized
with community-acquired pneumonia after adjusting for
other potential confounders including a propensity score
based upon the use/non-use of statins at presentation.
Methods
This a retrospective cohort study of patients hospitalized
with community-acquired pneumonia at 2 academic ter-
tiary care hospitals in San Antonio, Texas. Both hospitals
are teaching affiliates of the University of Texas Health Sci-
ence Center at San Antonio. The Institutional Review
Board of the University Health Science Center at San
Antonio approved the research protocol with exempt
status.
Study Sites/Inclusion and Exclusion Criteria
We identified all patients admitted to the study hospitals
between January 1, 1999 and December 1, 2002 with a
primary discharge diagnosis of pneumonia (ICD-9 codes
480.0–483.99 or 485–487.0) or secondary discharge diag-
nosis of pneumonia with a primary diagnosis of respira-
tory failure (518.81) or sepsis (038.xx). Subjects were
included if they were 1) greater than 18 years of age, 2)
had an admission diagnosis of community-acquired
pneumonia, and 3) had a radiographically confirmed
infiltrate or other finding consistent with community-
acquired pneumonia on chest x-ray or CT obtained within
24 hours of admission.
Exclusion criteria included 1) having been discharged
from an acute care facility within 14 days of admission, 2)
transfer after being admitted to another acute care hospi-
tal, and 3) being comfort measures only on this admis-
sion. If a subject was admitted more than once during the
study period, only the first hospitalization was abstracted.
Data Abstraction
Chart review data included: demographics, comorbid
conditions, physical examination findings, laboratory
data, and chest radiograph reports. In addition, data on
important processes of care measures for patients hospi-
talized with community-acquired pneumonia were also
abstracted: first dose of antibiotics within 4 hours and 8
hours of admission, collection of blood cultures prior to
antibiotic administration, and obtaining blood cultures
and oxygen saturation measurement within 24 hours of
presentation [14]. Antimicrobial therapy was considered
guideline-concordant if it agreed with either the 2000
Infectious Diseases Society of America or 2001 American
Thoracic Society guidelines [15,16]. Information on all
outpatient medications that were either 1) reported as cur-
rently being taken by the patient at presentation, or 2)
listed in the electronic medical record, were recorded.
Patients were defined as taking a statin if they had a statin
listed on the electronic medical record (as an outpatient
medication) or history and physical under outpatient
medications.
Mortality was assessed using information from the Texas
Department of Health and Department of Veteran Affairs
clinical database. Mortality status was assessed through
December 2002.
Risk Adjustment
The pneumonia severity index score was used to assess
severity of illness at presentation [17]. The pneumonia
severity index is a validated prediction rule for 30-day
mortality in patients with community-acquired pneumo-
nia. This rule is based on three demographic characteris-
tics, five comorbid illnesses, five physical examination
findings, and seven laboratory and radiographic findings
from the time of presentation. Patients are classified into
five risk classes with 30-day mortality ranging from 0.1%
for class I to 27% for class V for patients enrolled in the
PORT cohort study [17].
Outcome
We used 30-day mortality as the outcome for this study.
Previous research has demonstrated that 30-day mortality
is primarily due to the community-acquired pneumonia
rather than other co-existing co-morbid conditions
[18,19]. Therefore by using 30-day mortality as our out-
come we are able to minimize the effect of statin use on
other co-morbid conditions.
Sample Size
Sample size calculations were based on an assumption of
a 30% overall utilization of statins and a 40% difference
in use between those who died and survived. We calcu-
lated that 800 subjects were needed to have an 80%Respiratory Research 2005, 6:82 http://respiratory-research.com/content/6/1/82
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probability to detect a significant mortality difference at
30-days (with an α of 0.05 and β of 0.20).
Statistical Analyses
Univariate statistics were used to test the association of
sociodemographic and clinical characteristics with all-
cause 30-day mortality. Categorical variables were ana-
lyzed using the Chi-square test and continuous variables
were analyzed using Student's t-test.
A propensity score technique was used to balance covari-
ates associated with statin use between groups [20]. The
use of the propensity score technique provides a way, in
non-randomized studies, to control for pretreatment dif-
ferences by defining sets of comparable patients. The pro-
pensity score was derived from a logistic regression
model. A dichotomous indicator variable indexing
whether a patient was on a statin was our response varia-
ble. The covariates used in the propensity score model
were the pneumonia severity index score (which includes
comorbid conditions such as congestive heart failure, liver
disease, and history of stroke), history of alcoholism, his-
tory of diabetes mellitus, coronary artery disease, and cur-
rent tobacco use. Variables were entered, and maintained,
in the model if they had a p-value <0.20 in the univariate
analysis (with statin use as the dependent variable) and
had a p-value <0.20 in the final model.
We used a Cox proportional hazard model to estimate,
and graph, the baseline survivor functions after adjusting
for the propensity score and processes of care including
use of guideline-concordant antibiotics, initial dose of
antibiotics within 4 hours, obtaining blood cultures prior
to antibiotics and within 24 hours, and assessing oxygen-
ation at presentation.
A multivariable logistic regression model was derived
with 30-day mortality as the dependent variable, and the
propensity score, use of statin at presentation, and process
of care measures (initial antibiotics within 4 hours and
obtaining blood cultures prior to initial dose of antibiot-
ics, and whether antimicrobial therapy was guideline con-
cordant) as potential confounding variables. Interactions
were assessed using cross-product terms between the med-
ications and all of the other variables retained in the mod-
els. No significant interactions terms were noted, so they
were excluded from the final models. All analyses were
performed using STATA version 8 (Stata Corporation,
College Station, Texas).
Results
Data was abstracted on 787 patients at the two hospitals.
The mean age was 60 years with a standard deviation of 16
years. The population was 79% male, 84% were admitted
through the emergency department, and 20% were admit-
ted to the intensive care unit (ICU) within the first 24
hours after admission. Mortality was 9.2% at 30-days and
13.6% at 90-days. By pneumonia severity index, 52%
were low risk (pneumonia severity index classes I-III),
34% were moderate risk (pneumonia severity index class
IV), and 14% were high risk (pneumonia severity index
class V). Regarding community-acquired pneumonia-
related processes of care, 28% received the initial dose of
antibiotics within 4 hours of presentation and an addi-
tional 22% received the initial antibiotic dose within 8
hours, 76% of patients had blood cultures obtained
within 24 hours and prior to antibiotics, and oxygenation
was assessed at presentation in 91%.
Table 1 shows the demographic factors, clinical character-
istics, and processes of care data for this population by 30-
day mortality. In the univariate analysis numerous indi-
vidual components of the PSI were significantly associ-
ated with 30-day mortality including age, nursing home
residency, history of congestive heart failure, history of
malignancy, altered mental status, systolic blood pressure
< 90 mmHg, tachycardia> 125 beats per minute, arterial
acidosis, elevated blood urea nitrogen 30 mg/dl, serum
sodium < 130 meq/l, and pleural effusion on chest radio-
graph. The only processes of care that were statistically sig-
nificant were the assessment of oxygenation within 24
hours or presentation and use of guideline-concordant
antibiotics. Statin use had only a borderline significance
(p = 0.07) in the univariate analysis.
Of the 787 subjects, 110 subjects (14%) were on statins at
presentation. Table 2 demonstrates the association
between clinical and demographic variables and the use/
non-use of statins. Components of the PSI that were sig-
nificantly associated with statin use include increased age,
history of congestive heart failure, history of stroke, systo-
lic blood pressure < 90 mmHG, and an elevated serum
glucose. History of diabetes mellitus was also associated
with statin use. Conditions inversely associated with sta-
tin use include: nursing home residence, history of alco-
holism, chronic liver disease, current tobacco use, and
pleural effusion on chest x-ray. Figure 1 displays the %
survival by statin-use versus non-use over 30-days after
adjusting for the propensity score and processes of care,
showing that statin use is associated with higher survival
at 30-days (p = 0.001).
In the multivariable regression analysis, after adjusting for
the propensity score and processes of care, the use of stat-
ins at presentation (odds ratio 0.36, 95% confidence
interval 0.14–0.92) was significantly associated with
decreased 30-day mortality.Respiratory Research 2005, 6:82 http://respiratory-research.com/content/6/1/82
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Discussion
We found that prior outpatient use of statins was associ-
ated with decreased 30-day mortality for subjects hospi-
talized with community-acquired pneumonia. Our
findings provide further support to previous work that
demonstrate that statin use is associated with decreased
mortality for patients with acute bacterial illnesses
[12,13]. Further studies are needed to examine the impact
of statins, both pre-hospitalization and acute, on patients
hospitalized with community-acquired pneumonia and
other bacterial illnesses.
Our study, with a methodologically stronger cohort
design, supports the findings of the recent case-control
study which demonstrated that patients hospitalized with
bacteremia who were on statins at admission had a signif-
icant reduction in in-hospital mortality (28% versus 6%,
p<0.002) [12]. In the multivariate analysis, after adjust-
ment for confounding factors (including comorbid condi-
tions, age, concurrent medications, site of infection, vital
signs, and laboratory data) not being on a statin (odds
ratio 7.6, 95% confidence interval 1.01–57.5) was signifi-
cantly associated with mortality. This prior research, com-
bined with our results, supports the need for further
research to examine the impact of statins in the treatment
of infectious diseases.
Table 1: Subject Demographic and Clinical Characteristics by 30-Day Mortality*
Variable 30-Day Mortality
Alive (n= 715) Dead (n= 72) p-valzue
Age, years +/- standard deviation 60.2+/-16.4 62.9 +/-16.4 0.09
Men 561 (79) 60 (83) 0.3
Nursing home resident 41 (6) 13 (18) <0.001
Admitted through emergency department 598 (84) 58 (81) 0.5
Admitted to intensive care within 24 hours 118 (17) 36 (50) <0.001
Preexisting Comorbid Conditions
Congestive heart failure 105 (15) 18 (25) 0.02
Chronic pulmonary disease 195 (27) 23 (31) 0.4
History of stroke 93 (13) 12 (17) 0.4
Chronic liver disease 83 (12) 11 (15) 0.4
History of malignancy 58 (8) 20 (28) <0.001
Renal insufficiency 74 (10) 13 (18) 0.05
History, Physical, Laboratory, and Radiographic Data
Altered mental status 68(10) 17(24) <0.001
Respiratory rate > 30 per minute 71 (10) 11 (15) 0.2
Systolic blood pressure < 90 mmHg 16 (2) 5 (7) 0.02
Heart rate > 125 per minute 86 (12) 19 (26) 0.001
Temperature < 95° or > 104°F 19 (3) 2 (3) 0.9
Arterial pH < 7.35 37 (5) 12 (17) <0.001
Arterial oxygenation saturation < 90% 149 (21) 27 (38) 0.001
Hematocrit < 30% 64 (9) 8 (11) 0.5
Serum blood urea nitrogen > 30 mg/dL 135 (19) 33 (46) <0.001
Serum glucose > 250 mg/dL 71 (10) 5 (7) 0.4
Serum sodium < 130 meq/L 98 (14) 18 (25) 0.01
Pleural effusion on chest radiograph 160 (11) 29 (35) 0.001
Pneumonia Severity Index
Class I-III 393 (54) 16 (22)
Class IV 240 (34) 26 (36)
Class V 82 (12) 30 (42) <0.001
Processes of Care
Initial antibiotics within 4 hours 201 (28) 22 (31) 0.7
Initial antibiotics within 8 hours 358 (50) 36 (50) 1.0
Blood cultures prior to antibiotics 540 (76) 55 (76) 0.9
Oxygenation assessed ≤ 24 hours 538 (75) 65 (90) 0.004
Guideline-concordant antibiotics used 574 (80) 51 (71) 0.05
Outpatient Medications
Statin 105 (15) 5 (7) 0.07
* Data are presented as number (%) or mean +/-standard deviationRespiratory Research 2005, 6:82 http://respiratory-research.com/content/6/1/82
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Although our study was retrospective and subject to the
recognized limitations of such studies, we carefully assem-
bled our cohort from complete patient discharge data to
avoid ascertainment bias. Additionally, during chart
abstraction we encountered a very small amount (<5%) of
missing data. Our sample was predominantly men due to
the inclusion of a VA hospital and it is possible, but
unlikely, that women may have differential responsive-
ness to statins as compared to men. Also we are unable to
assess factors such as duration of statin use, inpatient
continuation of the statin, or the dose effect due to the
design of this study. In addition we are unable to control
for quality of health care that patients had prior to hospi-
talization. Further research is needed to examine these fac-
tors. Finally, as in any non-experimental study, we are
unable to state conclusively that the prior outpatient use
of statin is the cause of decreased mortality in this cohort.
However, since patients on statins have numerous medi-
cal conditions that are significantly associated with
increased short-term morality we feel that we have good
evidence that these medications may have beneficial
effects for patients hospitalized with community-acquired
pneumonia.
Conclusion
Our study finds that prior outpatient use of statins reduces
mortality for patients hospitalized with community-
acquired pneumonia. Our results add an additional
potential benefit of statin use to the already compelling
data for their use in patients with coronary artery disease,
hypercholesterolemia, diabetes, and peripheral vascular
disease. Additionally, patients with diabetes and vascular
disease are at higher risk for either contracting pneumonia
or dying from pneumonia when they do contract it. Fur-
ther studies are needed to confirm the magnitude of the
impact of statins, either pre-hospitalization or acute, on
Table 2: Use versus non-use of statin by demographic and clinical characteristics*
Variable Statin
Not on statin (n = 677) On statin (n = 110) p-value
Age, years +/- standard deviation 59.4+/-16.8 66.3+/-12.3 <0.001
Men 529(78) 92(84) 0.2
Nursing home resident 51(8) 3(3) 0.06
Admitted through emergency department 570(84) 86(78) 0.1
Admitted to intensive care within 24 hours 135(20) 19(17) 0.5
Preexisting Comorbid Conditions
Diabetes Mellitus 168(25) 62(56) <0.001
Alcoholism 79(12) 5(5) 0.03
Current tobacco use 217(32) 18(16) 0.001
Congestive heart failure 99(15) 24(22) 0.05
History of stroke 78(12) 27(25) <0.001
Chronic liver disease 91(13) 3(3) 0.001
History of malignancy 68(10) 10(9) 0.8
Renal insufficiency 74(11) 13(12) 0.8
History, Physical, Laboratory, and Radiographic Data
Altered mental status 76(11) 9(8) 0.3
Respiratory rate > 30 per minute 69(10) 13(11) 0.6
Systolic blood pressure < 90 mmHg 21(3) 0(0) 0.06
Heart rate > 125 per minute 96(14) 9(8) 0.09
Temperature < 95° or > 104°F 17(3) 4(4) 0.5
Arterial pH < 7.35 39(6) 10(9) 0.2
Arterial oxygenation saturation < 90% 151(22) 25(22) 0.9
Hematocrit < 30% 65(10) 7(6) 0.3
Serum blood urea nitrogen > 30 mg/dL 146(22) 22(20) 0.7
Serum glucose > 250 mg/dL 58(9) 18(16) 0.01
Serum sodium < 130 meq/L 105(15) 11(10) 0.13
Pleural effusion on chest radiograph 172(25) 17(15) 0.02
Pneumonia Severity Index
Class I-III 357(53) 52(47)
Class IV 222(33) 44(40)
Class V 98(14) 14(13) 0.3
* Data are presented as number (%) or mean +/-standard deviationRespiratory Research 2005, 6:82 http://respiratory-research.com/content/6/1/82
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patients hospitalized with community-acquired pneumo-
nia and to elucidate the mechanism by which they may
work.
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